BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results, Beats Estimates By $0.15 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its quarterly earnings data on Wednesday. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15, FiscalAI reports. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. During the same period in the previous year, the company posted $0.15 EPS. The company’s quarterly revenue was up 33.6% compared to the same quarter last year.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• ORLADEYO revenue rose 10% year over year to $158.2 million on a comparable basis, with continued new-prescriber additions, stable demand and an improved paid rate of 84%.
• The pediatric ORLADEYO pellets launch has begun strongly, with 47 prescriptions received by July 31—above the company’s full-year expectation—and early payer approvals and physician interest described as encouraging.
• BioCryst completed enrollment in the pivotal ALPHA-ORBIT trial of long-acting injectable navenibart ahead of schedule; top-line data are expected in the third quarter of 2027.
• The company raised 2026 total revenue guidance to $690 million-$715 million and lowered non-GAAP operating-cost guidance to $420 million-$440 million, supported by $113.2 million in second-quarter operating profit and more than $350 million in cash and investments.
• BioCryst is shutting down its Birmingham research unit and discontinuing internal discovery programs, shifting to externally sourced assets; management expects lower costs but must establish a stronger pipeline through future business-development transactions.

BioCryst Pharmaceuticals Trading Up 0.6%

NASDAQ BCRX opened at $9.07 on Thursday. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.22. The firm’s fifty day simple moving average is $9.32 and its 200-day simple moving average is $8.69. The company has a market capitalization of $2.31 billion, a PE ratio of -5.10 and a beta of 0.55.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BCRX. Focus Partners Wealth acquired a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $77,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $81,000. Elevation Point Wealth Partners LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $81,000. Cetera Investment Advisers increased its holdings in BioCryst Pharmaceuticals by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after buying an additional 1,494 shares during the last quarter. Finally, Quantessence Capital LLC acquired a new position in BioCryst Pharmaceuticals in the fourth quarter worth approximately $103,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on BCRX shares. Cantor Fitzgerald lifted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Wedbush reduced their price objective on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Royal Bank Of Canada raised their price objective on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.